Article
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Nature medicine - 1 May 2022
Kim Edward S, Velcheti Vamsidhar, Mekhail Tarek, Yun Cindy, Shagan Sarah M, Hu Sylvia, Chae Young Kwang, Leal Ticiana A, Dowell Jonathan E, Tsai Michaela L, Dakhil Christopher S R, Stella Philip, Jin Yanling, Shames David S, Schleifman Erica, Fabrizio David A, Phan See, Socinski Mark A
Abstract excerpt
Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST ( NCT02848651 ), an open-label, phase 2 trial that evaluated bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB-IVB non-small...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.